Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 119Carcinoma, Hepatocellular 69Ovarian Neoplasms 63Neoplasms 36Carcinoma, Non-Small-Cell Lung 34Fallopian Tube Neoplasms 29Brain Neoplasms 24Glioblastoma 22Colonic Neoplasms 21Breast Neoplasms 19Neoplasm Metastasis 18Endometrial Neoplasms 18Stomach Neoplasms 16Uterine Cervical Neoplasms 15Rectal Neoplasms 14Lung Neoplasms 14Liver Neoplasms 11Triple Negative Breast Neoplasms 10Melanoma 8Glioma 8Carcinoma, Renal Cell 8Carcinoma, Ovarian Epithelial 8Biliary Tract Neoplasms 8Colorectal Cancer Metastatic 7Squamous Cell Carcinoma of Head and Neck 6Recurrence 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Gastrointestinal Neoplasms 6Advanced Solid Tumors 6Small Cell Lung Carcinoma 5

Interventions

trifluridine tipiracil drug combination 1Nivolumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite-stable Colorectal Cancer × Bevacizumab × 1 year × Clear all
NCT07011550 2026-03-20

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Suspended
7 enrolled
Gastrointestinal

Microsatellite-stable Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡